Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01731496 · ClinicalTrials.gov registry record · NA
The Efficacy of Reminders to Complete HPV Series
A NA study, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 749
- Enrollment target
NCT01731496: Completed NA study, sponsored by University of Rochester.
NCT01731496 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 749 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01731496, a NA study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 749 participants
- Enrollment target
Study Summary
The human papillomavirus (HPV) vaccine is routinely recommended for both adolescent girls and boys starting at age 11, although it can be offered as young as 9 years of age. This is a 3-dose series and many adolescents do not complete it after getting the first dose. This study will study how effective it will be to send reminders to parents to schedule an appointment when their child is due for the next dose of HPV. Parents can chose whether they would like a phone call or text message reminder. This study will determine if the reminders work, and if one method is better than another (phone message vs. text message).
Primary Outcome
Post intervention HPV vaccination rates will be summarized by intervention group with frequencies and proportions, and will be compared between groups using chi square or Fisher's exact test as appropriate
Interventions
- OTHER Telephone reminder
- OTHER Text Message reminder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 749 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-10 |
| Phase | NA |
What the finished NCT01731496 record still lists
NCT01731496 is an interventional study that assigns participants to a tested intervention. The registered 749 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Telephone reminder is the first listed.
NCT01731496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01731496 about?
NCT01731496 is a clinical study titled "The Efficacy of Reminders to Complete HPV Series". The human papillomavirus (HPV) vaccine is routinely recommended for both adolescent girls and boys starting at age 11, although it can be offered as young as 9 years of age. This is a 3-dose series and many adolescents do not complete it after getting the first dose. This study will study how effect...
What is the current status of trial NCT01731496?
This trial is currently completed. It is a NA study. The enrollment target is 749 participants. The study started on 2012-04. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01731496?
The interventions under investigation include: Telephone reminder (OTHER), Text Message reminder (OTHER).
Who is sponsoring clinical trial NCT01731496?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01731496's enrollment target sits among peer trials
749 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia